increas outlook slightli chang
expect moat fve
updat forecast estim jul
conduct analyst
govern code ethics/cod conduct
polici secur trade polici
equival invest research
interest visit
primari analyst cover compani
stock
research jul
estim jul
price data jul
rate updat jul
currenc amount express
busi strategi outlook
methodolog valu compani
busi strategi outlook
busi system aim
continu improv scientif technolog portfolio
seek attract market acquir compani
enter expand within nich acquisit danah
aim acceler core growth acquir compani make
 marketing-rel invest also implement lean
manufactur principl administr cost control boost
oper margin overal appreci compani strateg
move push attract scientif tool market
strong growth prospect sticki recur revenu
stream exampl recur revenu stood close
sale
compani acquisition-focus strategi contribut
becom player highli fragment
rel sticki life scienc diagnost tool market
year first acquisit space radiomet
recent life scienc diagnost acquisit includ
beckman coulter pall cepheid earli
announc plan acquir fill
gap within biopharmaceut develop
manufactur tool market deal close expect later
year especi appreci attract qualiti
biopharmaceut develop manufactur market
includ strong growth trajectori high margin high
switch cost associ regulatori reproduc
concern end user
also continu prune portfolio busi
compani largest divestitur share publicli trade fortiv
corp distribut directli sharehold
second half compani plan separ dental
segment organ initi public offer
intend sell dental busi initi
expect remain long term sharehold
dental busi suffer commodif
core market weak demand trend
valuat summari forecast
financi summari forecast
historical/forecast data sourc morningstar estim may reflect adjust
founder transform real estat organ
industrial-focus manufactur compani seri merger
acquisit divestitur includ fortiv separ
danah focus primarili manufactur scientif instrument
consum four segment life scienc sale
diagnost environment appli solut dental
plan separ dental busi
organ initi public offer also plan
acquir biopharma busi add life scienc
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
increas outlook slightli
chang expect moat fve jul
result juli beat consensu expect
caus manag increas guidanc slightli
full year howev updat view remain roughli
line expect full year
anticip chang per share fair valu estim
remain moder recent share price
second quarter turn billion sale
report growth core growth intern
growth led life scienc diagnost
core growth
environmental/appli solut segment grew
dental segment remain drag organ
slight declin period life scienc
beckman coulter pall franchis grew high
singl digit continu benefit strong growth
trend biopharmaceut end market diagnost
compani legaci franchis appear solid recent
acquir cepheid molecular diagnost turn
growth quarter appear benefit
dbs-relat initi dental compani
tradit consum equip continu
declin contribut segment margin
pressur along on-going invest china also
remain solid contributor growth
quarter despit gener headwind countri
portfolio manag activ remain track
well compani still aim purchas ge biopharma
near end ipo dental segment
call envista remain track second
half year activ attract
danah busi qualiti perspect
compani look set cut exposur rel low-
margin slow-grow dental segment boost
exposur rel high-margin faster-grow
life scienc busi also moat perspect
ge biopharma acquisit significantli
danah exposur biopharmaceut develop
manufactur busi sticki
attract opinion howev signific invest
capit paid could keep return invest
capit near capit cost sever year
influenc view compani moat
increas fair valu estim
per share incorpor slightli higher organ
growth sale free cash flow valuat
assum acquir near end
fulli divest dental segment next coupl
year continu make tuck-in acquisit
averag billion annual
add growth prospect valuat
impli price/adjust earn multipl approxim
result trend view full year
core growth prospect increas
compani strong core growth solid margin
perform manag increas lower end
adjust earn per share outlook rang
view earn versu
remain roughli line expect
materi chang firm long-term prospect
forecast averag annual organ growth
around pro forma basi
slightli previou organ assumpt also
includ pend acquisit
dental segment separ futur unannounc tuck-in
acquisit assum net activ add
basi point top-lin growth annual
segment expect organ growth
annual basi life scienc continu
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
annual next five year free cash flow rise
even faster pace compound annual
period use weight averag cost capit
roughli discount assumpt
stabl result firm acquisition-focus strategi
especi firm attempt acceler acquisit
target growth innov mean
bull-cas scenario result per share fair valu
estim scenario incorpor organ growth
base case scenario driven significantli
higher growth assumpt segment except dental
stronger growth higher margin
busi on-going cost control project
oper margin rise
assum base case scenario adjust
earn per share free cash flow grow
respect compound annual basi next
bear-cas scenario result per share fair valu
estim scenario incorpor organ growth
base case scenario compani
innov engin stall weaker growth new
product margin probabl would rise
significantli assum oper margin reach
assum base case
scenario adjust earn per share free cash
flow grow respect compound annual
basi next five year
dental oper acquisit
benefit grow demand trend particularli
develop manufactur biopharmaceut
expect addit ge biopharma boost
segment growth trajectori annual
forecast period report basi factor
compound annual growth diagnost segment
next five year rel high growth
cepheid molecular diagnost constrain
matur legaci brand environment appli
solut also expect organ growth annual
next five year demand rel
high margin tool remain solid dental segment
assum busi continu grow low-singl
digit next coupl year compani
continu grappl commodif weak
demand trend core dental product
compani integr higher margin ge biopharma
busi control cost gener project
firm profit rise substanti specif
expect oper margin rise
overal base case scenario incorpor
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
activ cut return invest capit
recent year narrow moat rate recogn
attract fundament qualiti core busi
appear like sustain return capit cost
least next year specif see intang
asset switch cost moat sourc
gener compani offer differenti technolog
protect variou intang asset includ
patent brand copyright trademark
intang asset weight averag remain life
year show length exclus
surround intellectu properti although quicker
innov cycl evolv nich like reduc
relev life protect product
intang asset prevent ident copycat long
period time sinc even slightli differenti technic
featur caus end user prefer one tool
anoth similar tool specif applic
precis scientif end market see intang asset
around differenti technolog
also product chosen due differenti
featur specif applic often abl
layer substanti switch cost-rel advantag
tool enabl essenti oper
client switch competitor technolog could
chang outcom oper would
undesir user product
incorpor process overal
danah revenu stream recur natur
major sale consid captiv mean
custom use anoth supplier want keep
use instrument equip least
sale dynam highlight razor/razor blade
model pursu
differenti
technolog howev sustain danah
competit advantag differ product set
believ life scienc segment estim
revenu pro forma pend ge biopharma
acquisit enjoy lengthiest sustain competit
advantag underli basi differenti
proprieti tool affect perform
accuraci speed variou research project
enabl differenti product
intang asset inform decis use tool
specif applic begin research
project order remain relev scientist earli
research phase must continu innov
contribut intang asset busi well
howev initi decis made see
particularli sticki busi drug develop
manufactur tool repres half
life scienc segment acquisit
close estim product danah
serv biopharmaceut firm discoveri new
molecul product medicin danah
product chosen end user part product
process molecul begin clinic trial
process client unlik switch supplier
addit molecul success market
revenu stream would like continu product
life cycl discoveri patent expir danah
could gener recur revenu year small
molecul even longer difficult-to-manufactur
biolog bode well sustain
econom profit gener busi rest
segment see narrow moat gener
shorter project howev concern reproduc
custom test result cours research
project creat inertia switch
technolog period also academ
earli stage research custom feed stickier busi
regulatori
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
drug develop manufactur scientist
train danah product earli career may
apt continu use tool certain applic
career progress
diagnost pro forma sale provid
broad set toolsinclud clinic chemistri
immunoassay hematolog tissue-bas molecular
diagnost -- sell primarili hospit physician
offic refer lab use patient blood urin
tissu sampl econom moat busi
deriv mix intang asset switch cost
get diagnost system place lab initi relat
differenti featur proprietari
technolog contribut intang asset moat
sourc segment howev place regular
use see switch cost advantag danah
diagnost tool specif displac use
establish diagnost platform challeng
competitor sinc lab hesit disrupt system
integr practic pathologist
particularli loyal influenc diagnost platform
even test rel simpl scientif
custom often show loyalti tool make
work-lif easier high autom broad set
test option would also note
diagnost segment sale consid recur
highest percentag danah
environment appli solut pro forma
sale also benefit intang asset
switch cost although think lean heavili
intang asset segment
segment highlight segment rel even
split recur versu non-recur revenu
tool segment appear differenti variou
featur includ speed accuraci reproduc
result howev segment product benefit
long use live dedic consum requir
continu use product
break-out sale product line two major brand
hach videojet hach municip custom
purchas water qualiti diagnost tool requir
dedic reagent run relat test also
videojet printer place consum good
manufactur use danah rapidli dri ink print best
date lot code rapidli flow product
line hach videojet busi initi
purchas equip use live roughli five
year life instrument consum sale
typic account time price initi
equip purchas also offer servic
tool segment long-term contract
creat anoth recur revenu stream
equip place sticki busi like
make larg portion segment think
environment appli solut contribut
histor view dental pro forma sale
busi posit moat weak demand
segment offer basic dental
consum differenti dental implant
orthodont tool constrain segment growth
profit recent year overal current
see dental segment signific contributor
danah moat expect chang
danah hold period busi initi
public offer dental busi later
also would surpris see reduc
stake complet tax implic declin
also investor know compani acquisit
activ strateg attract may constrain
return invest capit includ goodwil
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
diagnost busi recogn price trend
especi wake on-going protect access
medicar act pama -relat reimburs cut
center medicar medicaid servic
diagnost test could cut return busi
eventu far seen evid
trend hurt diagnost demand margin
significantli one could argu highli autom
system standard test offer supplier like
could benefit price sensit time howev
keep close eye on-going price dynam
commodif core dental segment product
constrain top-lin result margin enough us
view segment neg contributor danah
moat trend howev neutral slightli posit view
segment off-set neg take
enough us view moat trend stabl
exposur rel
forese futur exampl plan
acquir billion net tax benefit
time ebitda plan sell stake dental
segment investor initi public offer
recogn activ attract
busi qualiti perspect compani look set
low-margin
slow-grow dental segment boost exposur
rel high-margin faster-grow life scienc
busi also moat perspect ge biopharma
acquisit significantli increas exposur
biopharmaceut develop manufactur
busi one could argu wide moat
characterist howev signific invest capit
paid could keep return invest capit
near capit cost sever year valuat
us could constrain return go forward
 activ continu unab given
import acquisit organ expans
strategi expect remain key capit alloc
prioriti danah on-going activ could
eventu cut current narrow moat see enough
posit attribut underli busi on-going
return maintain rate
overal moat trend remain stabl base underli
fundament trend although differ slightli
segment life scienc think decis
expand reach biopharmaceut develop
manufactur tool acquisit
improv profit overal oper
enhanc moat sourc segment howev
valuat offer pend acquisit temper
view transact somewhat environment
appli solut see stabl trend overal
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
focus
acceler core growth margin expans
market initi innov
appear posit growth prospect
orec expans highli valu life scienc
diagnost market requir larg outlay
capit includ goodwil eaten
odanah shift healthcar market creat
less cyclic busi attract market high
entri
face signific competit target
nich must remain dedic on-going
relev
plenti opportun consolid
improv perform variou fragment
oth dental segment continu suffer low
growth weak margin firm aim
turnaround prospect along initi public
offer uncertainti surround whether
possibl hold period
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
equival begin period
total avail debt servic
oblig commit
total oblig commit
adjust free
gener
gener revolv adjust
commit
de-lever
flexibl capit market access import recent
year compani issu debt make signific
acquisit beckman coulter pall
cepheid
manag level acquir ge biopharma
estim gross leverag increas
time end time
transact close pro forma basi compani
willing boost financi leverag make ge
biopharma acquisit put even pressur deal
opinion posit though express
desir maintain
investment-grad statu
de-lever think compani de-lever
expect profit growth activ debt repay
initi public offer dental segment could
provid opportun materi reduc leverag
assum fulli sell hold organ
stabl result firm acquisition-focus strategi
underli basi compani scientif technolog
gener predict revenu stream life
scienc demand product larg
influenc health biopharmaceut academ
research develop budget current remain
strong uncorrel econom cycl diagnost
compani sell system relat consum
hospit lab laboratori capit budget
fall prey econom cycl comfort
busi reli recur sale
segment one-tim system sale also on-going
pama-rel reimburs cut may cut
price power diagnost player eventu
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
far seen evid environment
appli solut segment essenti natur
water qualiti tool custom concentr
rel defens consum packag good
beverag industri bode well segment demand
even challeng time pend dental separ
eventu reduc depend
somewhat econom sensit market remain
concern acquisit strategi
expand target market activ creat
integration-rel risk also target market
richli valu recent year eaten return
invest capit overpay acquisit
may abl gener econom profit also
compani typic use debt leverag financ
deal compani quickli de-lever
debt-fund transact reason acquisit could
eventu harm financi flexibl
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
repres date owner name posit common share held report holder issuer
fidel manag research compani
new york mellon corp
share
fund
share
fund
firm biggest risk relat on-going appetit
acquisit
histor perform
manag align sharehold make danah
acquisition-rel declin return invest capit
reason concern maintain favor view
manag invest decis strateg
perspect focus asset industri
attract characterist combin manag
abil improv oper perform
danah busi system includ lean-manufactur
japanes system continu
improv empow leadership focus
custom need combin enabl
becom major player attract market materi
improv mani acquir busi impair
rare compani support view
manag follow disciplin acquisit strategi
integr process think dental segment
manag intend separ
initi public offer one area
under-perform compani recent histori
appreci decis separ busi focu
attract opportun
cofound brother mitchel steven rale retain
influenc compani root real estat
firm found refocus
steven rale chairman board
mitchel rale chair board execut committe
brother cumul approxim danah
outstand share thoma joyc join
becam ceo follow mani previou
leadership posit compani recent
water qualiti life scienc diagnost segment
joyc also join rale brother compani
board donald ehrlich lead independ
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
director board sinc director
elect annual execut compens remain
highli variabl signific concentr
equity-bas award align manag
sharehold opinion howev sharehold
note short-term incent payment
cash determin primarili adjust earn per
share free cash flow core revenu growth
metric move long-term incent plan
equiti award roic remain pressur
due valuat paid recent pend
acquisit life scienc diagnost remain
somewhat concern chang manag
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
boost narrow-moat fve higher growth
take fresh look boost
fair valu estim per share reflect
higher growth prospect relat pend ge
biopharma acquisit ad busi
contribut sustain competit
advantag well boost exposur sticki
biopharmaceut develop manufactur
busi overal attract underli fundament
busi contribut narrow moat
rate despit constraint return invest capit
relat on-going acquisit activ
plan acquir
billion net tax benefit time ebitda plan
sell stake dental segment investor
initi public offer recogn activ
attract busi qualiti perspect
compani look set cut exposur rel
low-margin slow-grow dental segment boost
exposur high-margin moderately-grow life
scienc busi howev signific invest capit
paid could keep return invest capit
near capit cost sever year also compani
willing boost financi leverag make ge
biopharma acquisit put pressur deal
opinion posit prune dental
segment could provid opportun materi reduc
leverag acquisit
valuat perspect believ share
moder overvalu share close
premium per share fair valu estim
june trade roughli time project earn
fair valu estim valu stock time
earn incorpor organ revenu growth
adjust earn per share growth free cash
flow growth compound annual next
initi coverag fair valu
estim narrow moat exemplari stewardship
launch coverag diversifi industri
fair valu estim stock current
star territori trade roughli fair valu
spun firm
busi model fortiv busi system fb
extens success danah busi system
root continu improv philosophi
compani drive oper margin expans
lean manufactur principl redeploy cash flow
 activ
although integr part firm strategi
believ individu busi fortiv portfolio
also merit narrow moat stand-alone basi due
custom switch cost intang asset
rel high recur revenu current compos
sale benefit larg instal base
across busi furthermor recent acquisit
focus boost recur revenu enhanc
firm softwar capabl fortiv seek combin
larg instal base equip complementari
softwar offer custom integr packag
think enhanc custom sticki
lastli believ fortiv manag merit
exemplari stewardship rate ceo jame lico two
decad experi despit rel
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
young compani experienc manag
team impress track record capit alloc
improv margin acquir compani consid
exemplari stewardship narrow moat think
like continu outearn cost capit
mani year come
continu review transfer
coverag new analyst expect publish new fair
valu estim later may
place review transfer
coverag new analyst expect publish new fair
valu estim second quarter
mostli favor outlook danah plan
acquir biopharma busi billion
approxim billion includ expect
billion tax benefit mani way acquisit isnt major
surpris sinc busi fit mold danah
strateg direct -- high growth high margin busi
larg stream consum sticki custom
product chromatographi system biopharma
asset share signific amount strateg overlap
danah exist life scienc busi overal dont
expect dramat shift fair valu estim
incorpor acquisit model also
dont expect chang narrow moat rate view
transact increment posit danah
think purchas price impli roughli time
ebitda look fair especi given segment high
exposur biopharma custom group boost
danah exposur attract portion life
scienc market biopharma custom segment
offer higher growth outlook thank demand biolog
drug develop manufactur also sticker
base user around regul input approv
pharmaceut product manag expect
growth asset may conserv
manag like priorit invest higher
growth portion busi single-us
technolog gene therapi product
thank larg part larg consum mix near
sale alreadi high profit manag
see million cost synergi three year
impli impress ebitda margin near
manag also expect initi boost
adjust ep first year like doubl within five
past year purchas
life scienc diagnost market
manag will take long-term view return
invest capit high single-digit return expect
five year
lastli expect deal close fourth
quarter financ deal cash hand new debt
issu near billion equiti like
inherit pension liabil ge manag
expect bbb credit rate follow transact
manag also announc intend ipo
dental busi -- potenti share initi
issu -- rather previou spin-off plan
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
bear window narrow thesi play ge
sell biopharma feb
agre sell biopharma busi
approxim billion includ billion cash
assumpt certain pension liabil time
forward ebitda specul deal
possibl earli last year wrote deal would
approxim billion current forward enterpris
value/ebitda multipl unit join
danah life scienc stand-alon busi
pharmaceut diagnost current form part
ge life scienc stay remaind ge
healthcar busi suppli contrast media
molecular imag consum radiolog custom
carve-out clearli make sens us given synergi
remain ge healthcar core medic imag
busi still evalu full impact
transact mostli time overli surpris
deal dont expect materi chang ge
fair valu estim per share
express interest busi earli
spring report wall street journal
time howev ge reportedli interest
pursu deal ge lose one bright star
typic increas top line high-single-digit
year-over-year clip think ceo larri make
right strateg decis first deal may make
life scienc valuat current high deal offer
team opportun de-lever balanc
sheet second believ ge life scienc littl
strateg valu futur industri infrastructur
final perhap importantli asset price discoveri
valuabl asset rel line
expect contrast bear assert ge
forc fire sale desir asset
dig self-impos debt hole
believ bear argument
particularli concern ge capit liabil thu
far seem less pronounc initi fear furthermor
ge gener adjust industri free cash flow
billion oper futur remain
strain power believ confirm thesi
ge highli desir asset exceed current
expect fulli valu time
ge transport merger close feb
updat explicit forecast expect
concurr file week
though currenc tariff repres small hurdl
plan make adjust model narrow-
moat compani fourth-quart result
larg keep compani line expect
manag outlook adjust ep
initi forecast think like
compani start year conserv tone
especi modest headwind china-rel
tariff combin neg currenc effect econom
growth concern china also dont seem affect
compani far manag note on-going broad-
base double-digit growth countri quarter
recent result expect organ
growth quarter life scienc segment
remain highest growth divis thank larg part
growth beckman life scienc sciex phenomenex
pall segment pall particular continu wit
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
double-digit growth among biotech custom group
rate manag note greater stabil
 market healthi perform china
still earli stage launch clear align
busi could add nice tailwind dental
segment lead expect spin-off busi
later year lastli growth diagnost
growth environment appli segment mostli
match forecast
fourth-quart oper margin bit
weaker anticip basi point
form last year dont anticip materi shift
futur profit assumpt addit acquisition-
currency- tariff-rel pressur bottom line
also
invest certain
initi clear align opportun dental
segment regardless long term still see
integr effici improv effort well
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
financi summari forecast
fiscal year end decemb
earn interest tax
return asset
return equiti
valuat summari forecast
equiti
pre-tax debt
weight averag capit
addit estim scenario avail download http //select morningstar com
equival
data tabl repres base-cas forecast compani report
currenc begin current year fair valu estim may differ
equiti valu per share shown due time valu money adjust case
probability-weight scenario analysi perform
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
